Literature DB >> 27073516

Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.

Yu-Jie Dong1, Yi-Ran Cai1, Li-Juan Zhou1, Dan Su1, Jing Mu1, Xue-Jing Chen1, L I Zhang1.   

Abstract

The present study aimed to investigate the association between epidermal growth factor receptor (EGFR)/Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements and the morphological characteristics of lung adenocarcinoma (LAC), according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification in a large group of patients with primary LAC. A total of 200 patients with invasive LAC who had undergone complete resections at the Beijing Chest Hospital (Beijing, China) were randomly selected. The morphology of the samples was reassessed in 5% increments by two pathologists, according to the IASLC/ATS/ERS scheme. EGFR and KRAS mutations were tested by direct DNA sequencing. ALK rearrangements were screened by immunohistochemistry on a Benchmark XT stainer. The data revealed that EGFR and KRAS mutations, and ALK rearrangements were identified in 46.0% (92/200), 9.0% (18/200) and 11.5% (23/200) of the patients, respectively. The EGFR/KRAS mutations and ALK rearrangements were mostly exclusive. However, 1 patient exhibited the coexistence of the EGFR (at exon 20) and KRAS (codon 12) mutations, and another patient exhibited the coexistence of the EGFR mutation (at exon 21) and the ALK gene fusion. EGFR mutations were indicated to be closely associated with the acinar predominant (43/77; 55.8%; P=0.030) and papillary predominant (26/49; 53.1%; P=0.006) subtypes. KRAS mutations were more commonly associated with the solid predominant subtype (9/52; 17.3%; P=0.023) and invasive mucinous LAC (5/10; 50.0%; P=0.004), and less commonly associated with the acinar predominant subtype (1/77; 1.3%; P=0.002). ALK rearrangements more commonly occurred in the solid predominant subtype compared with other subtypes (13/52; 25%; P=0.002), and less commonly occurred in the papillary predominant subtype (1/49; 2.0%; P=0.004). Tumors harboring ALK rearrangements were characterized by signet-ring cell (7/9; 77.8%; P<0.0001) and cribriform (7/12; 58.3%; P<0.0001) patterns. The association between the mutation status and histological subtype in LAC was distinct. The predominant subtype according to the IASLC/ATS/ERS classification provided important information for gene mutations and integrated clinical findings to improve the treatment of LAC patients.

Entities:  

Keywords:  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society; histological subtype; lung adenocarcinoma; mutation status

Year:  2016        PMID: 27073516      PMCID: PMC4812186          DOI: 10.3892/ol.2016.4233

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

1.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

2.  Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Authors:  Akihiko Yoshida; Koji Tsuta; Harumi Nakamura; Takashi Kohno; Fumiaki Takahashi; Hisao Asamura; Ikuo Sekine; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Hitoshi Tsuda
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

3.  Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.

Authors:  Jinghui Wang; Yujie Dong; Yiran Cai; Lijuan Zhou; Shafei Wu; Guimei Liu; Dan Su; Xi Li; Na Qin; Jingying Nong; Hongyan Jia; Quan Zhang; Jing Mu; Xuan Zeng; Haiqing Zhang; Shucai Zhang; Zongde Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-18       Impact factor: 4.553

4.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.

Authors:  Yi-Ran Cai; Hai-Qing Zhang; Yang Qu; Jing Mu; Dan Zhao; Li-Juan Zhou; Hong Yan; Jian-Wei Ye; Yan Liu
Journal:  Oncol Rep       Date:  2011-06-15       Impact factor: 3.906

6.  Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

Authors:  Ryu Jokoji; Takashi Yamasaki; Seigo Minami; Kiyoshi Komuta; Yasushi Sakamaki; Kengo Takeuchi; Masahiko Tsujimoto
Journal:  J Clin Pathol       Date:  2010-10-09       Impact factor: 3.411

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

9.  Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.

Authors:  DA-Ping Yu; Yu-Jie Dong; Hai-Qing Zhang; Jing-Hui Wang; Yang Qu; Li-Juan Zhou; Dan Su; Li-Li Zhang; Dan Zhao; Yi-Ran Cai
Journal:  Biomed Rep       Date:  2014-03-20

10.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

View more
  9 in total

1.  Circulating tumor cells in lung cancer: cluster circulating tumor cells as hybrid epithelial-mesenchymal transition/mesenchymal-epithelial transition (E/M).

Authors:  Noriyoshi Sawabata
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

2.  Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.

Authors:  Varsha Singh; Prerna Guleria; Prabhat Singh Malik; Anant Mohan; Sanjay Thulkar; R M Pandey; Kalpana Luthra; Sudheer Arava; Ruma Ray; Deepali Jain
Journal:  Curr Probl Cancer       Date:  2018-12-17       Impact factor: 3.187

3.  Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma.

Authors:  Yinglei Liu; Xiangyun Ye; Yongfeng Yu; Shun Lu
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma.

Authors:  Yan Li; Yan Tan; Song Hu; Jun Xie; Zhantao Yan; Xian Zhang; Yun Zong; Han Han-Zhang; Qing Li; Chong Li
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

5.  Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.

Authors:  Mio Mori; Hideyuki Hayashi; Minoru Fukuda; Sumihisa Honda; Takeshi Kitazaki; Kazuto Shigematsu; Naohiro Matsuyama; Mayumi Otsubo; Takeshi Nagayasu; Mikiko Hashisako; Kazuhiro Tabata; Masataka Uetani; Kazuto Ashizawa
Journal:  Thorac Cancer       Date:  2019-02-27       Impact factor: 3.500

6.  A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma.

Authors:  Thinh T Nguyen; Hyun-Sung Lee; Bryan M Burt; Jia Wu; Jianjun Zhang; Christopher I Amos; Chao Cheng
Journal:  Genome Med       Date:  2022-01-12       Impact factor: 11.117

7.  Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.

Authors:  Mengnan Zhao; Cheng Zhan; Ming Li; Xiaodong Yang; Xinyu Yang; Yong Zhang; Miao Lin; Yifeng Xia; Mingxiang Feng; Qun Wang
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 8.  Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.

Authors:  Lanlan Liu; Xianzhi Xiong
Journal:  Curr Oncol       Date:  2021-12-24       Impact factor: 3.677

9.  Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement.

Authors:  Qiongqiong Gao; Pupu Li; Xiangli Jiang; Zhongli Zhan; Qingna Yan; Bo Zhang; Chun Huang
Journal:  Oncotarget       Date:  2017-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.